Institutional Biosafety Committee Minutes

The Institutional Biosafety Committee (IBC) met on Tuesday, June 16, 2026 at 1:00 p.m. via videoconference. Upon reaching a quorum, the meeting was called to order by the Chairperson.

Meeting Attendance:

Ron Javier, PhD, Chair
Robert Atmar, MD, IBC Vice Chair
Connor Cordray, MPH, CPH, CHMM, CBSP
Monica Darden, MA
Julia Goldman, DVM
Shirley Hutchins, MSN
James Kelaher, MD
Robin Parihar, MD
Kevin Pope
Lisa Rollins, MS
Shannon Ronca, PhD, MPH, BS
Poonam Sarkar, PhD

Vance Hobbs, MBA, Alternate Member
Shalaka Kotkar, PhD, MPH, CPH, CBSP, Alternate
Leticia McGuffey, Alternate Member
Brooke Mitchell, Alternate Member
Holly Robinson, Alternate
Shubhashish Sarkar, PhD, Alternate Member
Rebecca, Schwiebert, PhD, DVM

CONFLICTS OF INTEREST

The Chairperson reminded the committee members about the conflict of interest (COI) policy and process. Any conflicts of interest recognized or declared during the meeting will be documented below. The affected member(s) will be excused from the meeting during the relevant discussion and vote and will not participate in either.

MEETING CONDUCT

The Chairperson reminded the committee members that all protocols that are discussed at the meeting are to be considered confidential due to potential privacy or proprietary concerns and are not to be discussed outside of the meeting room with non-IBC members. For this reason, this meeting is considered closed.

REVIEW OF May 2026 MINUTES

The minutes for May 19, 2026, IBC meeting were reviewed and a motion was made to approve the minutes as written. With the majority of the members present voting for the motion, the vote count for approval of the minutes was as follows:

For:	12
Abstain:	0
Against:	0

RECOMBINANT OR SYNTHETIC NUCLEIC ACID MOLECULES RESEARCH APPLICATIONS REVIEW

During the review the committee assessed the appropriate biocontainment levels as well as the facilities, procedures, practices, and training of the PI and laboratory personnel involved in the research including appropriate and relevant training, safe conduct of the research, and knowledge of recombinant or synthetic nucleic acids molecules research. The committee also reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences, nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and if so, the protein that will be produced. Furthermore, the committee determined the applicable section(s) of the NIH Guidelines.

It was determined that the chair or IBC member assigned by the chair must review the modifications to assure that all required changes have been made and all required training is complete before an approval letter may be sent and the PI may begin the research. Further questions, or changes requiring more than simple concurrence by the PI and the chair/designee will be brought to the next convened meeting for full committee review.

A. <u>Recombinant or synthetic nucleic acid molecules research -- Full Board New/Renewals</u>

Protocol number: D1012
PI: Martin, James
Containment Level: BSL-2
NIH Guidelines Section: III-D, III-E and III-F
Title: Recombinant or Synthetic Nucleic Acid Molecule Research in Porcine Models

This study evaluates a gene therapy approach to promote cardiac regeneration after myocardial infarction (MI) in heart muscle cells. Researchers will use AAV vectors to determine whether controlled, temporary activation of certain pathways can enhance heart function..

After the presentation by the assigned reviewer and discussion, the committee requested the following modifications: 1). Please implement a 3-day washout period after injection 2) Please provide a SOP for housing BSL2 pigs at THI.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the

motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D30
PI: Cheng, Jizhong
Containment Level: BSL-2
NIH Guidelines Section: III-D
Title: Chronic Kidney Disease Adversely Impaires Vascular Remodeling

This study investigates the molecular mechanisms that drive diseases such as diabetes, hypertension, and chronic kidney disease by using recombinant DNA and various common laboratory viral vectors to manipulate gene expression in bacterial cells, mammalian cells, and animal models. The study will evaluate how specific genes and signaling pathways influence cell function through molecular, cellular, and histological analyses.

After the presentation by the assigned reviewer and discussion, the committee requested the following modifications: 1). Please add AAV to the project description in Section C 2) Please remove T057 in Section D 3) Please define AVF in Section C.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D134
PI: Sun, Zheng
Containment Level: BSL-2
NIH Guidelines Section: III-D
Title: Epigenomic Regulation of Metabolism by Nuclear Receptor Corepressors

This study investigates how nuclear receptor regulate metabolism, cancer, brain function, and cardiovascular disease using genetically engineered mouse models, cell culture systems, and recombinant viral vectors. Researchers will use several viral vectors to selectively manipulate gene expression in the liver, brain, muscle, adipose tissue, mammary gland, and heart.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D181
PI: Decker, William
Containment Level: BSL-2
NIH Guidelines Section: III-D and III-E
Title: Th-1 Dendritic Cell Immunotherapy for The Treatment of Neoplasia

This study supports the development and evaluation of immune-based cancer therapies by creating tumor cell lines and study treatment responses in animal models. Pancreatic, breast, melanoma, and other cancer cell lines will be implanted into mice, and tumor burden will be measured over time using imaging, allowing researchers to assess therapeutic efficacy without repeatedly sacrificing animals.

After the presentation by the assigned reviewer and discussion, the committee requested the following modifications: 1). Please expand the abbreviation PDAC and TNBC in Section C 2) Please elaborate on antitumor therapy in Section C 3) Please provide the HAHC protocol number if the antitumor therapy belongs to group of chemotherapeutic drugs in Section C.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D500
PI: McGinley, Matthew
Containment Level: BSL-2
NIH Guidelines Section: III-D and III-F
Title: AAV and CAV Viral Usage for Understand Neural Circuit Function

This project seeks to understand how using genetically targeted viral tools, behavioral testing, imaging, and electrophysiological recording affect mice. Researchers will use viral vectors to selectively activate, silence, monitor, or ablate defined neural cells affect the brain state and neural activity.

After the presentation by the assigned reviewer and discussion, the committee requested the following modifications: 1). Section C: a. Please mention how long after viral gene transfer the mice will be imaged. b. Please describe the decontamination of animal bedding after any imaging experiment.2) Please explain how the vectors are being contained.3) Please select safety glasses in Section D8 4) Please ensure all personnel complete The Safe Use of rDNA in Research Training Course

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D514
PI: Krishnan, Vaishnav
Containment Level: BSL-1
NIH Guidelines Section: III-D
Title: Targeted Viral Based Treatments for Epilepsy Spectrum Disorders

This study investigates the relationship between several epilepsy disorders by using mouse models to examine how specific neural circuits and epilepsy-related genes influence behavior, mental health, and seizure susceptibility. Researchers will use adeno-associated viral vectors to selectively activate or inhibit neurons allowing assessment of their effects on behavioral, cognitive, and seizure-related outcomes.

After the presentation by the assigned reviewer and discussion, the committee requested the following modification: 1). Please explain the use of fluorescence tagged viral constructs in the experiment.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D578
PI: Chao, Hsiao-Tuan
Containment Level: BSL-2
NIH Guidelines Section: III-D, III-E and III-F

Title: Pathogenesis of Ebf3-Related Hadd Syndrome and Neurodevelopmental Disorders

This project investigates the genetic and molecular basis of EBF3-related HADD syndrome and other neurodevelopmental, neurological, and psychiatric disorders using cell culture systems, genetically engineered mice, and fruit fly models. Researchers study the gene functions by analyzing disease-associated variants, interacting proteins, and downstream targets.

After the presentation by the assigned reviewer and discussion, the committee requested the following modification: 1). Please remove the non-associated animal protocol from the protocol.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D850
PI: Nelson, David
Containment Level: BSL-1
NIH Guidelines Section: III-D and III-F
Title: Genetic, Molecular and Behavioral Studies of Fragile X Tremor Ataxia using Adeno-Associated Virus (AAV) Delivery Of CGG Repeat RNA In Mice and Cultured Cells

This study aims to identify genetic modifiers and disease mechanisms of Fragile X-associated syndromes using AAV-based mouse and cell culture models that express genes of interest.Using common viral vectors inmice and cultured cells, researchers will evaluate how candidate modifier genes influence disease-related molecular changes.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D852
PI: Mohamed, Tamer

Containment Level: BSL-2
NIH Guidelines Section: III-D, III-E and III-F
Title: Endogenous Heart Regeneration Through Induction of Cardiac Reprograming and Cardiomyocyte Proliferation

This study aims to develop regenerative therapies for heart failure following myocardial infarction (heart attack) by stimulating heart muscle cells. Researchers use molecular cloning, gene therapy, modified RNA technology, and non-replicating viral vectors to deliver genes that promote and restore cardiac function in cell culture systems and animal models.

After the presentation by the assigned reviewer and discussion, the committee requested the following modification: 1). Please indicate what kind of studies will be done on these tissues in Section C.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D648
PI: Ramos, Carlos
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: Besta: A Phase 1 Study Evaluating The Safety and Activity of Allogeneic Cd30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (Cd30.Car-Ebvsts) in Patients with Relapsed or Refractory Cd30-Positive Lymphomas

This study evaluates the safety, feasibility, and antitumor activity of a CAR T-cell therapy for patients with relapsed or refractory CD30-positive lymphoma. The therapy uses readily available genetically modified T cells instead of autologous products to improve treatment accessibility, reducing manufacturing time and cost, and minimizing the risk of graft-versus-host disease.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D836
PI: Barto, Tara
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: A Phase 1/2 Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of VX-522 in Subjects 18 Years of Age and Older with Cystic Fibrosis and a CFTR Genotype Not Responsive to CFTR Modulator Therapy

This open-label dose-escalation study evaluates the safety, tolerability, and preliminary efficacy of an inhaled mRNA therapy that delivers functional proteins to the lungs of patients with cystic fibrosis. Participants receive the therapy alone or in combination with standard therapy to determine the treatment's safety profile and therapeutic potential.

After the presentation by the assigned reviewer and discussion, the committee requested the following modification: 1). Please Clarify why this study is being renewed, if this study was previously asked to stop due to the tolerability issues.

Next, a motion was made and seconded to table the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the table of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D846
PI: Nicholson, Erin
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: A Phase 1/2a Trial of the Safety, Tolerability and Immunogenicity of PIV5-vectored RSV Vaccine (BLB-201) in RSV Seronegative and Seropositive Infants and Children

This clinical trial evaluates the safety, tolerability, and immunogenicity of a live vaccine engineered to express certain RSV proteins, for the prevention of respiratory syncytial virus (RSV) disease in infants and young children. Participants receive one or two doses or placebo, with follow-up assessments including adverse event monitoring, respiratory virus testing, and measurement of RSV-specific immune responses to determine the vaccine's safety profile and ability to generate protective immunity.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D855
PI: Omer, Bilal
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: Chimeric Antigen Receptor Treatment Targeting Aml And Other Cd70 (Seventy) Positive Leukemias – Casey

This clinical trial evaluates the safety, feasibility, and preliminary antileukemic activity of specific CAR T-cell therapy in patients with relapsed or refractory acute myeloid leukemia (AML). The investigational therapy uses T cells with the goal of inducing remission, and potentially enabling eligible patients to proceed to allogeneic hematopoietic stem cell transplantation.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

B. Recombinant or synthetic nucleic acid molecules research -- Full Board Amendments

Protocol number: D345

PI: Deneen, Benjamin
Containment Level: BSL-2
NIH Guidelines Section: III-D
Title: Developmental Analysis of Glial Fate Determination in The Central Nervous System

This project investigates the molecular and cellular mechanisms that regulate cell development, function, and disease in the central nervous system by manipulating key genes. Researchers will study transcription factors and signaling pathways that control cell development, while also study behavioral testing, electrophysiology, and transcriptomic analyses to determine how certain cells influence neural circuit activity and brain function.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D502
PI: Steffin, David
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: Gd2 Specific Chimeric Antigen Receptor and Interleukin-15 Expressing Autologous Natural Killer T-Cells to Treat Children wth Neuroblastoma (Ginakit2)

This clinical trial evaluates the safety, tolerability, and preliminary antitumor activity of T cell therapy in children and young adults with relapsed or refractory high-risk neuroblastoma. The evaluate activity in the immunosuppressive tumor microenvironment, with the goal of improving tumor control and long-term therapeutic responses.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D568
PI: Mandel, Jacob
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: H-43268: Gbm-001: An Open-Label, Multi-Center Trial of Ino-5401 And Ino-9012 Delivered By Electroporation (Ep) In Combination with Regn2810 in Subjects with Newly-Diagnosed Glioblastoma (Gbm)

This clinical trial evaluates the safety, immunogenicity, and preliminary efficacy of a DNA vaccine regimen for patients with newly diagnosed glioblastoma multiforme. The vaccine consists of plasmid DNA encoding the tumor-associated antigens to stimulate an antitumor immune response.

After the presentation by the assigned reviewer and discussion, the committee requested the following modification: 1). Please clarify if the genes are considered oncogenes in Section D .2) Please clarify the cloning of toxin molecules in Section D 3) Please complete Section D5 4) Please ensure all personnel complete the required training.

Next, a motion was made and seconded to approve the protocol with modifications required to secure approval. The motion passed with a majority of the members present voting for the motion. The vote count for the approval of the protocol with modifications required to secure approval was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D838
PI: Suter, Bernhard
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: RTT-200: Baseline-Controlled, Open-Label Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability Of NGN-401 in Subjects with Rett Syndrome (Emboldentm))

This multicenter study evaluates the safety, efficacy, and tolerability of gene therapy designed to treat Rett syndrome (RTT) by delivering a regulated copy of the human genes directly into the central nervous system through a single infusion. The therapy incorporates technology to control gene expression and reduce the risk of overexpression, addressing the underlying genetic cause of RTT in females with genetically confirmed classic disease.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D927
PI: Patel, Meera
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab with or without V940 in Participants with Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy (INTerpath-009)

This study evaluates the safety and effectiveness of a personalized mRNA cancer vaccine, in combination with standard therapy for patients with resected Stage II–III non-small cell lung cancer who did not achieve a complete response after neoadjuvant therapy. The vaccine is individually designed from each patient's tumor and blood samples to stimulate tumor-specific immune responses.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D957
PI: Bacino, Carlos
Containment Level: BSL-2
NIH Guidelines Section: III-C

Title: H-50899 / A Study to Evaluate the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of Intrathecally Administered Ion582 in Patients with Angelman Syndrome

his study evaluates the safety, tolerability, and long-term effects of an antisense oligonucleotide therapy for Angelman Syndrome that targets and degrades specific RNA to restore expression of target genes, which are normally silenced in affected individuals. Participants receive multiple ongoing assessments of neurological function, biomarkers, pharmacokinetics, MRI findings, EEG patterns.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

Protocol number: D976
PI: Nayak, Anuranjita
Containment Level: BSL-2
NIH Guidelines Section: III-C
Title: EMPEROR: A Multicenter, Randomized, Double-Blind, Sham-Controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability Of Zorevunersen (STK-001) in Patients with Dravet Syndrome

This study evaluates the efficacy, safety, and tolerability of an antisense oligonucleotide therapy designed to treat Dravet syndrome. Patients will be randomized to receive either study drug or a control, with the goal of reducing seizures and improving other disease-related symptoms by addressing the underlying genetic cause of the disorder.

Following the presentation by the assigned reviewer and discussion of the protocol, the committee IBC concluded that all aspects of review and approval criteria (described above) were met.

Next, a motion was made and seconded to approve the protocol. The motion passed with a majority of the committee members present voting for the motion. The vote count for the approval of the protocol with all applicable approval criteria was as follows: For, 12; Against, 0; Abstaining, 0.

There were no members who recused and absented themselves during the discussion and vote on this protocol due to a conflict of interest.

C. Recombinant or synthetic nucleic acid molecule Closure Administrative Report
The IBC Laboratory Compliance Assurance Associate reported to the IBC that there was no rDNA IBC protocol closed for the month of June.

D. Recombinant or synthetic nucleic acid molecule Minor Administrative Report
The IBC Laboratory Compliance Assurance Associate reported to the IBC that there were five administrative rDNA IBC protocols for the month of June.

E. Recombinant or synthetic nucleic acid molecules research -- Exempt Protocols
The IBC Laboratory Compliance Assurance Associate reported to the IBC that there was no exempt protocol submitted in the month of June.

F. IBC Inspection Report
The Biosafety Officer (BSO) informed the committee that there were seven inspections performed for the month of June.

G. Research Compliance Services (RCS) Update
The IBC Laboratory Compliance Assurance Associate informed the committee that there were three post-approval monitoring sessions.

H. Member Discussion
There were no items to report for the month of June.
.

I. Spills, Incidents, or Exposures
There were no items to report for the month of June.

J. RAC Decisions and Updates
There were no items to report for the month of June.

K. Issues from the Floor and Public Comments
There were no issues raised from the floor or public comments.

L. Adjournment
The meeting was adjourned at 1:55 pm

UPCOMING EVENTS:
The next IBC meeting is scheduled for Tuesday, July 21, 2026.